Crossmark

3′-deoxy-3′-18F-fluorothymidine PET imaging of lymphoid tissues in patients with advanced non-small cell lung cancer undergoing anti-programmed cell death-1 therapy

Crossref DOI link: https://doi.org/10.1186/s13550-025-01225-7

Published Online: 2025-04-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Sato, Masayuki

Umeda, Yukihiro https://orcid.org/0000-0002-9826-6856
Tsujikawa, Tetsuya

Mori, Tetsuya

Shimada, Akikazu

Sonoda, Tomoaki

Yamaguchi, Makiko

Honjo, Chisato

Waseda, Yuko

Kiyono, Yasushi

Ishizuka, Tamotsu

Okazawa, Hidehiko
Funding

Funding for this research was provided by:

MEXT KAKENHI (JP22K07688)
License Information

Text and Data Mining valid from 2025-04-01

Version of Record valid from 2025-04-01
More Information

Article History

Received: 28 October 2024

Accepted: 12 March 2025

First Online: 1 April 2025

Declarations

:

: All methods were performed in accordance with the ethical standards of the Declaration of Helsinki and its later amendments, or with comparable ethical standards. This study was approved by the Research Ethics Committee of the University of Fukui (no. 20210150). The requirement for informed consent was waived by the ethics committee.

: Not applicable.

: The authors have no potential conflict of interest to declare.

Document is current

Any future updates will be listed below